Rami S Komrokji

Summary

Affiliation: H. Lee Moffitt Cancer Center and Research Institute
Country: USA

Publications

  1. ncbi Hypoalbuminemia is an independent prognostic factor for overall survival in myelodysplastic syndromes
    Rami S Komrokji
    H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida
    Am J Hematol 87:1006-9. 2012
  2. ncbi Advances in the management of myelofibrosis
    Rami S Komrokji
    Department of Malignant Hematology at the H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33617, USA
    Cancer Control 19:4-15. 2012
  3. ncbi Lenalidomide for treatment of myelodysplastic syndromes
    Rami S Komrokji
    H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612, USA
    Curr Pharm Des 18:3198-203. 2012
  4. ncbi Validation of the MD Anderson Prognostic Risk Model for patients with myelodysplastic syndrome
    Rami S Komrokji
    H Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA
    Cancer 118:2659-64. 2012
  5. ncbi Role of lenalidomide in the treatment of myelodysplastic syndromes
    Rami S Komrokji
    H Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA
    Semin Oncol 38:648-57. 2011
  6. ncbi Outcome of diffuse large B-Cell lymphoma in the United States has improved over time but racial disparities remain: review of SEER data
    Rami S Komrokji
    Department of Malignant Hematology, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
    Clin Lymphoma Myeloma Leuk 11:257-60. 2011
  7. ncbi Management of lower-risk myelodysplastic syndromes: the art and evidence
    Rami S Komrokji
    H Lee Moffitt Cancer Center and Research Institute, FOB 3rd Floor, 12902 Magnolia Drive, Tampa, FL 33612, USA
    Curr Hematol Malig Rep 6:145-53. 2011
  8. ncbi Outcome of patients with myelodysplastic syndromes in the Veterans Administration population
    Rami S Komrokji
    Department of Hematologic Malignancies, H Lee Moffitt Cancer and Research Institute, Tampa, FL 33612, USA
    Leuk Res 34:59-62. 2010
  9. ncbi Lenalidomide in myelodysplastic syndromes: an erythropoiesis-stimulating agent or more?
    Rami S Komrokji
    H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
    Curr Hematol Malig Rep 5:9-14. 2010
  10. ncbi Myelodysplastic syndromes classification and risk stratification
    Rami S Komrokji
    H Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, Tampa, FL 33612, USA
    Hematol Oncol Clin North Am 24:443-57. 2010

Detail Information

Publications18

  1. ncbi Hypoalbuminemia is an independent prognostic factor for overall survival in myelodysplastic syndromes
    Rami S Komrokji
    H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida
    Am J Hematol 87:1006-9. 2012
    ..Am. J. Hematol., 2012. © 2012 Wiley Periodicals, Inc...
  2. ncbi Advances in the management of myelofibrosis
    Rami S Komrokji
    Department of Malignant Hematology at the H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33617, USA
    Cancer Control 19:4-15. 2012
    ..Of the MPNs, MF presents with the most severe morbidity and greatest mortality. Although the cause of MF is unknown, it is thought to occur from acquired mutations that target the hematopoietic stem cell...
  3. ncbi Lenalidomide for treatment of myelodysplastic syndromes
    Rami S Komrokji
    H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612, USA
    Curr Pharm Des 18:3198-203. 2012
    ..We highlight the mechanism of action and the recent advances in understanding the biology of del (5q) MDS. We also explore its potential use and the efforts to further improve its activity in non-del (5q) MDS...
  4. ncbi Validation of the MD Anderson Prognostic Risk Model for patients with myelodysplastic syndrome
    Rami S Komrokji
    H Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA
    Cancer 118:2659-64. 2012
    ..We applied the MDAS to Moffitt Cancer Center (MCC) MDS patients to validate its prognostic utility...
  5. ncbi Role of lenalidomide in the treatment of myelodysplastic syndromes
    Rami S Komrokji
    H Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA
    Semin Oncol 38:648-57. 2011
    ..Finally, we highlight the current understanding of its mechanism of action, discussing the emerging insight into the underlying biology of del(5q) MDS and its linkage to potential targets of lenalidomide...
  6. ncbi Outcome of diffuse large B-Cell lymphoma in the United States has improved over time but racial disparities remain: review of SEER data
    Rami S Komrokji
    Department of Malignant Hematology, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
    Clin Lymphoma Myeloma Leuk 11:257-60. 2011
    ..Diffuse large B-cell non-Hodgkin lymphoma (DLBCL) outcome in the United States has not been reported outside the context of clinical trials...
  7. ncbi Management of lower-risk myelodysplastic syndromes: the art and evidence
    Rami S Komrokji
    H Lee Moffitt Cancer Center and Research Institute, FOB 3rd Floor, 12902 Magnolia Drive, Tampa, FL 33612, USA
    Curr Hematol Malig Rep 6:145-53. 2011
    ..We use a case-based format to discuss current options for treatment, including erythropoiesis-stimulating agents, hypomethylating agents, lenalidomide, immunosuppressive therapy, supportive care, and investigational agents...
  8. ncbi Outcome of patients with myelodysplastic syndromes in the Veterans Administration population
    Rami S Komrokji
    Department of Hematologic Malignancies, H Lee Moffitt Cancer and Research Institute, Tampa, FL 33612, USA
    Leuk Res 34:59-62. 2010
    ..MDS became reportable to the Surveillance, Epidemiology, and End Results Program (SEER) in 2001. We report first study of MDS among large population in the Veteran Affair system...
  9. ncbi Lenalidomide in myelodysplastic syndromes: an erythropoiesis-stimulating agent or more?
    Rami S Komrokji
    H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
    Curr Hematol Malig Rep 5:9-14. 2010
    ..This article reviews the clinical experience with lenalidomide, highlighting recent understanding of the dual karyotype-dependent mechanisms of action...
  10. ncbi Myelodysplastic syndromes classification and risk stratification
    Rami S Komrokji
    H Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, Tampa, FL 33612, USA
    Hematol Oncol Clin North Am 24:443-57. 2010
    ..This article reviews MDS classification and risk stratification highlighting differences between the various systems...
  11. ncbi Lenalidomide for treatment of myelodysplastic syndromes: current status and future directions
    Rami S Komrokji
    Department of Malignant Hematology, H Lee Moffitt Cancer Center and Research Institute, University of South Florida, 12902 Magnolia Drive, Tampa, FL 33612, USA
    Hematol Oncol Clin North Am 24:377-88. 2010
    ....
  12. ncbi Outcomes after induction chemotherapy in patients with acute myeloid leukemia arising from myelodysplastic syndrome
    Celeste Bello
    Department of Malignant Hematology, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612, USA
    Cancer 117:1463-9. 2011
    ..The authors evaluated predictive factors in patients with secondary AML treated with anthracycline-based induction therapy...
  13. ncbi Combined treatment with lenalidomide and epoetin alfa in lower-risk patients with myelodysplastic syndrome
    Rami S Komrokji
    Department of Hematologic Malignancies, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL and
    Blood 120:3419-24. 2012
    ..The benefits of lenalidomide plus rhu-EPO are currently under investigation in a phase 3 Eastern Cooperative Oncology Group (ECOG)-sponsored intergroup study. This study is registered at www.clinicaltrials.gov as NCT00910858...
  14. ncbi Cutaneous manifestations in CMML: Indication of disease acceleration or transformation to AML and review of the literature
    Rahel A Mathew
    University of South Florida, School of Medicine, Tampa, FL, USA
    Leuk Res 36:72-80. 2012
    ..8 months. Overall survival from diagnosis to the last follow-up in patients with LC was 28.2 months, shorter than patients without LC (44 months). LC and its equivalent could predict disease progression to AML...
  15. ncbi Outcome of azacitidine treatment in patients with therapy-related myeloid neoplasms with assessment of prognostic risk stratification models
    Vu H Duong
    H Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA
    Leuk Res 37:510-5. 2013
    ..Response rates were comparable to those reported for de novo myelodysplastic syndrome. When we analyzed outcomes according to five scoring systems, only the Global MD Anderson Risk Model predicted survival with statistical significance...
  16. ncbi Expansion of effector memory regulatory T cells represents a novel prognostic factor in lower risk myelodysplastic syndrome
    Adam W Mailloux
    Immunology Department, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
    J Immunol 189:3198-208. 2012
    ..Based on these findings, Treg(EM) cell expansion may be synonymous with human Treg activation and indicate microenvironmental changes conducive to transformation in myelodysplastic syndromes...
  17. ncbi Severe hypoalbuminemia at day 90 predicts worse nonrelapse mortality and overall survival after allogeneic hematopoietic stem cell transplantation for acute myelogenous leukemia and myelodysplastic syndrome
    Mohamed A Kharfan-Dabaja
    Department of Blood and Marrow Transplantation, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612, USA
    Biol Blood Marrow Transplant 17:384-93. 2011
    ..These results support day 90 hypoalbuminemia as an adverse prognostic marker for NRM and OS after allo-HCT for acute myelogenous leukemia and myelodysplastic syndrome...
  18. ncbi Salvage chemotherapy regimens for acute myeloid leukemia: Is one better? Efficacy comparison between CLAG and MEC regimens
    Samantha L Price
    Department of Pharmacy, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA
    Leuk Res 35:301-4. 2011
    ..2% for MEC (P=0.09), with median OS of 11 and 4.5 months, respectively (P=0.07). In first relapse, CR was 36.8% and 25.9% (P=0.35) and median OS was 6.7 and 6.7 months, respectively (P=0.87). Our data support use of CLAG for RR-AML...